Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the thirteen research firms that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $78.67.
MLTX has been the topic of several research analyst reports. Needham & Company LLC cut their price objective on MoonLake Immunotherapeutics from $66.00 to $62.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Monday, July 1st. Finally, Oppenheimer initiated coverage on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 25th. They set an “outperform” rating and a $104.00 price objective for the company.
Get Our Latest Stock Analysis on MoonLake Immunotherapeutics
Institutional Investors Weigh In On MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Stock Up 1.8 %
Shares of NASDAQ:MLTX opened at $49.04 on Thursday. The business’s 50 day moving average is $43.59 and its 200 day moving average is $45.96. MoonLake Immunotherapeutics has a 12-month low of $35.11 and a 12-month high of $64.98. The stock has a market cap of $3.13 billion, a price-to-earnings ratio of -65.39 and a beta of 1.25.
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.11). During the same quarter in the prior year, the company earned ($0.23) EPS. As a group, equities research analysts expect that MoonLake Immunotherapeutics will post -1.21 earnings per share for the current year.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Further Reading
- Five stocks we like better than MoonLake Immunotherapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- The 3 Best Fintech Stocks to Buy Now
- 2 Option Strategies to Maximize Profits in a Bear Market
- 3 Stocks to Consider Buying in October
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.